Introduction {#Sec1}
============

Malaria is a public health problem reported worldwide especially in the African region (213 million or 93%), with an estimated 405,000 deaths from malaria globally in the year 2018^[@CR1]^. Human malaria is caused by five species of *Plasmodium* spp. including *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale*, and *P. knowlesi*^[@CR2]^. Microscopy and rapid diagnostic tests (RDTs) are diagnostic tools to confirm the diagnosis in patients suspected of having malaria^[@CR1]^. Currently, the microscopic method is the gold standard for malaria detection and diagnosis. However, it is imperfect by nature, especially in the identification of mixed-infections among residents in community-endemic areas. Sub-microscopic mixed-infections with low parasite density are commonly missed by microscopic methodologies^[@CR3]^. Therefore, mixed infections of *Plasmodium* spp. are often unrecognized and underestimated due to the low detection rate by microscopy (2%)^[@CR4],[@CR5]^. Misdiagnosis of *Plasmodium* mixed infections can lead to anti-malarial drug resistance and the development of severe malaria^[@CR6]^. RDTs are easy to use and cost effective. They play a crucial role in the control of malaria when microscopy is unavailable and are convenient to use in field surveys or remote areas where laboratory capacity is limited. RDTs are immunochromatographic lateral flow devices of which commonly targeting histidine-rich protein-2 (HRP2), lactate dehydrogenase (LDH), and aldolase RDTs for rapid malaria detection^[@CR7]--[@CR10]^. RDTs targeting HRP2 are specific for the detection of *P. falciparum*, while RDTs targeting LDH can be used for the detection of *P. falciparum*, *P. vivax*, or pan-specific (e.g., four *Plasmodium* species) LDH antibodies; aldolase is another common target for RDTs to detect all *Plasmodium* species^[@CR7]--[@CR10]^. Recently used commercial dipsticks for the detection of HRP-2 include PfHRP2 CareStart^[@CR11]--[@CR13]^, SD Bioline Malaria Ag Pf^[@CR14],[@CR15]^, and SD BIOLINE Malaria Ag P.f/Pan^[@CR16],^ and one recently used for the detection of pLDH is CareStart pLDH(pan)^[@CR15]^. A recently used commercial dipstick for the detection of Pan-aldolase is ParaHit Total, while a recently used commercial dipsticks for the detection of *P. vivax* aldolase is mAb 1C3-12 F10^[@CR17]^. Recently used commercial dipsticks for the detection of HRP-2/pLDH include SD BIOLINE Malaria Ag P.f/Pan^[@CR16]^ and CareStart malaria HRP2/pLDH (Pf/pan) Combo test^[@CR18]^. Finally, recently used commercial dipsticks for the detection of HRP-2/pan-aldolase include Malaria P.f/Pan Rapid Test Device Acon^[@CR19]^ and ParaHIT Total Dipstick^[@CR20]^.

Even though a large number of RDTs are available for malaria detection, the widespread use of RDTs causes the missed detection of mixed-species infections in individuals^[@CR21]^. Moreover, their performance for the detection of mixed-species infections is less requires well more comprehensive studies. Since the accurate detection of mixed-species infections of malaria is very critical for successful malaria control programmes, the objective of this systematic review and meta-analysis was to summarise and analyse the performance of malaria RDTs in detecting *Plasmodium* mixed infections. This study aims to highlight the big knowledge gap on the performance of malaria RDTs in detecting these mixed-species infections and to help make informed decisions on the use of RDTs for prompt treatment, which will help eliminate malaria in endemic and non-endemic areas.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Searches of Medline (PubMed), Web of Science, and Scopus were systematically performed using the search terms provided in Supplementary Table [S1](#MOESM1){ref-type="media"}. The searches were limited to the English language. Searches were carried out and finished on 1 April 2020. All reference lists of all eligible and included studies as well as Google Scholar search was performed to further increase the number of included articles for review.

Definition of malaria RDTs and microscopy {#Sec4}
-----------------------------------------

Types of malaria RDTs were classified according to the study by Bell et al.^[@CR7]^. They classified malaria RDTs into seven types according to the antigen used in the reagent strip, including type 1 (HRP2 (falciparum-specific), 2 (pf-HRP2/pan-aldolase), 3 (pf-HRP2/pan-pLDH), 4 (Pf-LDH/pan-pLDH), 5 (Pf/Pv --pLDH), 6 (pf-HRP2/Pv-pLDH), and 7 (aldolase). RDTs types 2, 3, 4, 5 and 6 can detect mixed or concurrent infections. Interpretation of *Plasmodium* mixed-infections by RDT was based on details provided by authors of the included studies. The gold standard for malaria detection is still microscopy where the examinations of thin and thick blood films lead to the demonstration of malaria parasites.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

Cross-sectional studies that reported the number of *Plasmodium* mixed infections evaluated by any of the five types of RDTs (types 2, 3, 4, 5 and 6) in comparison to microscopy or PCR were included in the present study. Studies reporting the results of RDTs and microscopy from the same patient samples or those reporting the results of RDTs and PCR from the same patient samples were included in the study. The following types of literature were excluded; studies that reported mixed-infections only for RDTs but did not report microscopy or PCR, incomplete data, no RDT results, co-infections with other agents, experimental studies, review articles, case reports and case series, polymorphism/mutation studies, knowledge about malaria/practice assessments, animal/mosquito studies, studies of haematological alterations, guidelines, and clinical drug trials. Studies with no full text and present data in the local language were also excluded.

Data extraction {#Sec6}
---------------

All studies acquired through the search were stored in EndNote reference manager software (version X9; Clarivate Analytics). The data extractions started with screening the titles and abstracts after duplicate studies removed. Studies that were not related to the inclusion criteria were excluded. Then, the studies were screened for full-text articles, and those that did not comply with eligibility criteria were excluded with tags indicating the reason for exclusion. The data from full-text articles that passed the inclusion and exclusion criteria were then exclusively examined and extracted by two independent authors (MK and KUK) using an Excel spreadsheet for further analysis. Any inconsistencies relating to included studies and data extraction were resolved by a third or a fourth reviewer (FRM or GDM).

Statistical analysis {#Sec7}
--------------------

Studies were grouped (subgroup) according to the different RDT types for comparative analysis. The meta-analysis of the proportion of the number of *Plasmodium* mixed infections per the total number of total malaria positives were performed as follows: (1) the summary estimate of the difference in the proportion (odds ratios, ORs) of RDTs to detect mixed infections compared with microscopy and (2) the summary estimate of the difference in the proportion (ORs) of RDTs to detect mixed infections compared with PCR methods were estimated. The subgroup analysis of RDT types, blood collection methods (finger prick or venipuncture), and types of *Plasmodium* mixed species confirmed by PCR were analysed in the present study. All analyses were conducted using Review Manager Version 5.3 (Cochrane, UK). The statistical analysis used to calculate the difference between groups was the Mantel--Haenszel test with a random-effects model. The meta-analysis for each study and the overall studies are presented with OR and 95% confidence intervals (CIs) as effect measures and summarized in forest plots. Cochrane's Q test and Higgins's I^2^ statistics were performed to assess the heterogeneity of the included studies.

Quality of included studies {#Sec8}
---------------------------

The quality of the individual studies included in the present study was assessed by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)^[@CR22]^. The tool includes 4 domains including the following: (1) report the review question, (2) develop review-specific guidance, (3) review the published flow diagram, and (4) judge bias and applicability. Each domain was assessed in terms of the patient selection, index test, reference standard, and flow timing. Patient selection was the method of patient selection reported in the included studies. The index test was the RDT method that was conducted and interpreted in the included studies. The reference standards were microscopy or the PCR method that was conducted and interpreted. The flow and timing described any patients who did not receive the index tests or reference standard. Each question was answered with a "yes," "no," or "unclear" response. The results of the QUADAS assessment for all included studies were then summarized in the methodological quality graph and summary created by Review Manager.

Publication bias {#Sec9}
----------------

Publication bias is the publication of studies due to the statistical significance of the results^[@CR23]^, which can lead to overestimated effect sizes and the dissemination of false-positive results^[@CR24]^. The publication bias was assessed by visual inspection of funnel plot asymmetry (the asymmetrical distribution of the included studies in the graph between the OR and SE (logOR)). The publication bias was also assessed with Egger\'s test. Both tests aimed to determine small-study effects leading to more or less beneficial summaries of OR estimates^[@CR25]^.

Results {#Sec10}
=======

Characteristics of the included studies {#Sec11}
---------------------------------------

The search retrieved 1,340 records. After removing 144 duplicates, 1,196 records were left for the title and abstract screening. Title and abstract screening resulted in the exclusion of 946 records. The full texts of 250 articles were assessed for their eligibility, and 231 of these were excluded with tags indicating the reason for exclusion. The most common reason for exclusion was no report of RDT in their articles. Other reasons for exclusion are shown in Fig. [1](#Fig1){ref-type="fig"}. As a result, 19 articles were included in the present study^[@CR26]--[@CR44]^. Further searches on the references of the selected publications which passed the inclusion criteria and Google Scholar search resulted in the inclusion of 9 additional articles^[@CR19],[@CR21],[@CR45]--[@CR51]^. Overall, 28 articles were selected, extracted, and analysed.Figure 1Study flow diagram.

Among the 28 articles included in the present study, 3 reported mixed infections by RDT type 2 (pf-HRP2/pan-aldolase) and microscopy^[@CR27],[@CR41],[@CR51]^, 13 by RDT type 3 (pf-HRP2/pan-pLDH) and microscopy^[@CR19],[@CR21],[@CR27],[@CR28],[@CR30],[@CR31],[@CR33],[@CR35],[@CR38],[@CR40],[@CR43],[@CR44],[@CR47]^, 3 by type 4 (Pf-LDH/pan-pLDH) and microscopy^[@CR34],[@CR36],[@CR51]^, 1 by RDT type 5 (Pf/Pv-pLDH)^[@CR46]^, and 9 by RDT type 6 (pf-HRP2/Pv-pLDH)^[@CR21],[@CR26],[@CR36],[@CR42],[@CR43],[@CR46],[@CR48]--[@CR50]^. Among 27 articles included in the present study, 1 reported mixed infections by RDT type 2 and PCR^[@CR32]^, 5 on RDTs type 3 and PCR ^[@CR21],[@CR28],[@CR33],[@CR43],[@CR45]^ and 5 by RDT type 6 and PCR^[@CR21],[@CR26],[@CR29],[@CR37],[@CR43]^. Most of the included studies (8/26, 30.8%) were conducted in Ethiopia^[@CR27],[@CR30],[@CR31],[@CR38],[@CR42],[@CR45],[@CR48],[@CR50]^, India (3/26, 11.5%)^[@CR32],[@CR39],[@CR49]^, and Kuwait (2/26, 7.7%)^[@CR34],[@CR46]^. Additional data are shown in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the included studies.No. (Ref.)AuthorStudy area (years of the survey)Participants (N)MicroscopyRDTsMolecular techniquesMalaria positiveMono infectionsMixed infectionsMethodManufacturersAntigenTypeMalaria positive2Mono infectionsMixed infectionsPCR method (gene)Malaria positiveMono infectionsMixed infections1. Ref.^[@CR26]^Alam et al., 2011Bangladesh (2009--2010)Febrile patients (338)1891863Thick and thin blood filmsOnsite Pf/Pv (CTK Biotech Inc, USA)pf-HRP2/Pv-pLDH61781735^d^Real-time PCR (18S rRNA)1881808FalciVax Pf (Zephyr Biomedicals, India)pf-HRP2/Pv-pLDH61911892^d^2. Ref.^[@CR27]^Ashton et al., 2010Ethiopia (2009)Febrile patients (2,383)5525439Thick and thin blood filmsCareStart (Access Bio, Inc., USA)pf-HRP2/pan-pLDH3716396320NDNDNDNDParaScreen (Zephyr Biomedicals, India)pf-HRP2/pan-pLDH3719383336ICT Combo (ICT Diagnostics, South Africa)pf-HRP2/pan-aldolase27373993383. Ref.^[@CR28]^Berzosa et al., 2018Equatorial Guinea (2013)Residents (1,741)6555800Thick and thin blood filmsNADAL Malaria 4 species test (Test cassette) (Nal von Minden, Germany)pf-HRP2/pan-pLDH3761527212Semi-nested multiplex PCR (18S rRNA)787772154. Ref.^[@CR19]^Bouyou et al., 2014Gabon (2013)Febrile patients (287)94931Thick and thin blood filmsSD BIOLINE Malaria Ag -Pf/Pan (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/pan-pLDH31031021^a^ND5. Ref.^[@CR48]^Chanie et al., 2011Ethiopia (2009--2010)Febrile patients (1,092)2262242Thick and thin blood filmsCareStart Malaria Pf/Pv Combo test (Access Bio, Inc., USA)pf-HRP2/Pv-pLDH62432394^d^ND6. Ref.^[@CR29]^Edwards et al., 2015Cambodia (2013--2014)Febrile patients (3,206)NDNDNDNDSD BIOLINE Malaria Ag P.f/P.v (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/Pv-pLDH61031012Reverse Transcription PCR (18S rRNA)174154207. Ref.^[@CR21]^Ehtesham et al., 2015Iran (2012)Malaria-positive (100)100982Thick and thin blood filmsFirst Response Malaria Antigen pLDH/HRP2 Combo (Premier Medical, India)pf-HRP2/pan-pLDH3917714Nested PCR (18S rRNA)1008812CareStart Malaria HRP-2/pLDH (Pf/pan) Combo (Access Bio, Inc., USA)pf-HRP2/pan-pLDH3907812CareStart Malaria HRP2/pLDH(Pf/Pv) Combo (Access Bio, Inc., USA)pf-HRP2/Pv-pLDH694877^d^8. Ref.^[@CR30]^Endeshaw et al., 2010Ethiopia (2007)Febrile patients (1997)47539184Thick and thin blood filmsParascreenPan/Pf (Zephyr Biomedicalsystems, India)pf-HRP2/pan-pLDH337229775^a^ND9. Ref.^[@CR31]^Feleke et al., 2017Ethiopia (2015--2016)Febrile patients (320)41365Thick and thin blood filmsCareStart Malaria HRP2/pLDH (Pf/PAN) Combo (Access Bio, Inc., USA)pf-HRP2/pan-pLDH343385^a^ND10. Ref.^[@CR45]^Getnet et al., 2015Ethiopia (2014)Febrile patients (359)NDNDNDNDCareStart Malaria HRP2/pLDH (Pf/PAN) Combo (Access Bio, Inc., USA)pf-HRP2/pan-pLDH3806614Not reported11679611. Ref.^[@CR32]^Haanshuus et al., 2016India (2011--2012)Febrile patients (1,564)NDNDNDNDParaHIT-Total Ver. 1.0 Device 55IC204-10 (Span Diagnostics Ltd, India)pf-HRP2/pan-aldolase2754627Nested PCR (18S rRNA)2682213012. Ref.^[@CR33]^Imwong et al., 2015VietnamResidents (2,177)2292250Thick and thin blood filmsSD BIOLINE Malaria Ag P.f/Pan POCT (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/pan-pLDH32242168Quantitative real-time PCR (18S rRNA)9885215613. Ref.^[@CR34]^Iqbal et al., 2001Kuwait (1997--1998)Febrile patients (515)16315112Thick and thin blood filmsOptiMAL (Pf-pLDH/pan-pLDH) (Biorad, France)Pf-LDH/pan-pLDH41421348^c^ND14. Ref.^[@CR46]^Iqbal et al., 2002Kuwait (1999--2002)Febrile patients (750)27124724Thick and thin blood filmsICT Malaria Pf/Pv (ICT Diagnostics, Australia)pf-HRP2/Pv-pLDH617816612^d^NDOptiMAL (Biorad, France)Pf/Pv -pLDH52302121815. Ref.^[@CR35]^Jahan et al., 2019Pakistan (2013)Febrile patients (2,033)35932039Thick and thin blood filmsFirst response Malaria Ag, pLDH/HRP2 Combo Card test kit (Premier Medical Corporation Ltd.)pf-HRP2/pan-pLDH32662239^a^Nested PCR (18S rRNA)9595016. Ref.^[@CR47]^Khorashad et al., 2014Iran (2009--2010)Febrile patients (178)52475Thick and thin blood filmsMalaria 102 (p.f/p.v) POCT kits (InTec Products Inc., China)pf-HRP2/pan-pLDH340355^a^ND17. Ref.^[@CR36]^Kim et al., 2008Korea (2003--2007)Malaria-positive (182)Healthy (100)1821790Thick and thin blood filmsOptiMAL (Biorad, France)Pf-LDH/pan-pLDH41741713^c^Conventional PCR (PvMSP-1, PfCSP-1)NDND3SD Malaria Antigen Pf/Pv (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/Pv-pLDH61721693^d^18. Ref.^[@CR37]^Li et al., 2016China (2011--2012)Febrile patients (103)NDNDNDNDMalaria Pv/Pf Test Device, Tycolpharm Co., Limited, UK)pf-HRP2/Pv-pLDH661601Nested PCR (18S rRNA)6966319. Ref.^[@CR49]^Meena et al., 2009India (2007)Febrile patients (1,189)71692Thick and thin blood filmsFalciVax (Orchid Biomedical Laboratories, India)pf-HRP2/Pv-pLDH675741^d^ND20. Ref.^[@CR44]^Mehlotra et al., 2019Madagascar (2015--2016)Febrile patients (963)4524520Thick and thin blood filmsSD BIOLINE Malaria Ag P.f/Pan (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/pan-pLDH346189372PCR/LDR-FMA5595352421. Ref.^[@CR38]^Moges et al., 2012Ethiopia (2011)Febrile patients (254)114986Thick and thin blood filmsCareStart Malaria HRP2/pLDH (Pf/pan) (Access Bio, Inc., USA)pf-HRP2/pan-pLDH31007426ND22. Ref.^[@CR39]^Ranjan P. and Ghoshal U, 2016India (2013--2015)Febrile patients (561)64640Thick and thin blood filmsNot reportedNot reportedNot reported92893Nested PCR (18S rRNA)7875323. Ref.^[@CR40]^Ratnawati et al., 2008Indonesia (2006)Febrile patients (89)785622Thick and thin blood filmsRapid One-Step Malaria test (Arista Biologicals Inc., USA)pf-HRP2/pan-pLDH3725022^a^ND24. Ref.^[@CR41]^Richter et al., 2004Germany (1999--2004)Febrile patients (674)69654Thick and thin blood filmsThe Now Malaria test (Binax, Inc., USA)pf-HRP2/pan-aldolase259284^b^ND25. Ref.^[@CR50]^Sharew et al., 2009Ethiopia (2008)Febrile patients (668)31430410Thick and thin blood filmsCareStart Malaria Pf/Pv Combo test (Access Bio, Inc., USA)pf-HRP2/Pv-pLDH633132110^d^NDvan den Broek et al., 2006Colombia (2005)Febrile patients (896)1401337Thick and thin blood filmsOptimal-IT (Diamed AG, Switzerland)Pf-LDH/pan-pLDH41341287^c^ND26. Ref.^[@CR51]^NOW Malaria ICT (Binax, USA)pf-HRP2/pan-aldolase21341268^b^ND27. Ref.^[@CR42]^Woyessa et al., 2013Ethiopia (2008--2010)Febrile patients (2,394)4794745Thick and thin blood filmsCareStart Malaria Pf/Pv combo test (Access Bio, Inc., USA)pf-HRP2/Pv-pLDH668667214^d^ND28. Ref.^[@CR43]^Yan et al., 2013Myanmar (2011)Febrile patients (350)988711Thick and thin blood filmsWondfo One Step Malaria HRP2/pLDH (P.f/Pan) Testpf-HRP2/pan-pLDH3936033Nested PCR (18S rRNA)1139221Malaria Pv/Pf test device (Tycolpharm Co., Limited, UK)pf-HRP2/Pv-pLDH690828^d^18 studies in total yielded identical results with RDT and microscopy.*ND* not determine.^a^Six studies (4, 8, 9, 15, 16, and 23) yielded identical results with RDT type 3 and microscopy.^b^Two studies (24 and 26) yielded identical results for RDT type 2 and microscopy.^c^Three studies (13, 17, and 26) yielded identical results for RDT type 4 and microscopy.^d^Nine studies (1, 5, 7, 14, 17, 19, 25, 27, and 28) yielded identical results for RDT type 6 and microscopy.

WHO product testing of malaria RDTs {#Sec12}
-----------------------------------

The WHO product testing of malaria RDTs began in 2008^[@CR52]^. All companies manufacturing malaria RDTs under the ISO-13485 Quality System Standard were invited to submit up to three tests for evaluation^[@CR52]^. The results of the WHO product testing of malaria RDTs are demonstrated in Table [2](#Tab2){ref-type="table"}. RDTs from the eight studies^[@CR30],[@CR34],[@CR36],[@CR40],[@CR41],[@CR46],[@CR49],[@CR51]^ were not subject to the WHO product testing program as these RDTs were developed and used before 2008, while the results of malaria RDTs from the four studies^[@CR28],[@CR37],[@CR43],[@CR47]^ was not found on the WHO testing product.Table 2Characteristic of *Plasmodium* mixed infections.No. (ref.)AuthorsMicroscopyRDTsPCR resultsPositivity*Plasmodium* spp.Blood collection methodsManufacturersAntigenWHO product testingFalse positive (%) *Plasmodium* spp. infection in clean-negative samplesNumber of mixed infectionsTypes of mixed infectionsNumber of mixed infectionsTypes of mixed infections1. Ref.^[@CR26]^Alam et al., 20113*P. falciparum*/*P. vivax*VenipunctureOnsite Pf/Pv (CTK Biotech Inc, USA)pf-HRP2/Pv-pLDHRound 205*P. falciparum*/*P. vivax*8*P. falciparum*/*P. vivax* (8)FalciVax Pf (Zephyr Biomedicals, India)pf-HRP2/Pv-pLDHRound 24.52*P. falciparum*/*P. vivax*2. Ref.^[@CR27]^Ashton et al., 20109*P. falciparum*/*P. vivax*Finger prickCareStart (Access Bio, Inc., USA)pf-HRP2/pan-pLDHRound 13.0320*P. falciparum*/*P. vivax*ParaScreen (Zephyr Biomedicals, India)pf-HRP2/pan-pLDHRound 11.2336*P. falciparum*/*P. vivax*ICT Combo (ICT Diagnostics, South Africa)pf-HRP2/pan-aldolaseRound 10.6338*P. falciparum*/*P. vivax*3. Ref.^[@CR28]^Berzosa et al., 20180Finger prickNADAL Malaria 4 species test (Test cassette) (Nal von Minden, Germany)pf-HRP2/pan-pLDHNot found in WHO product testing recordsNot found in WHO product testing records212Not specified15Not specified4. Ref.^[@CR19]^Bouyou et al., 20141*P. falciparum*/*P. malariae*VenipunctureSD BIOLINE Malaria Ag -Pf/Pan (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/pan-pLDHRound 41.31*P. falciparum*/*P. malariae*5. Ref.^[@CR48]^Chanie et al., 20112*P. falciparum*/*P. vivax*Finger prickCareStart Malaria Pf/Pv Combo test (Access Bio, Inc., USA)pf-HRP2/Pv-pLDHRound 204*P. falciparum*/*P. vivax*6. Ref.^[@CR29]^Edwards et al., 2015SD BIOLINE Malaria Ag P.f/P.v (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/Pv-pLDHRound 42.82*P. falciparum*/*P. vivax*20*P. falciparum*/*P. vivax* (19), *P. vivax*/*P. malariae* (1)7. Ref.^[@CR21]^Ehtesham et al., 20152*P. falciparum*/*P. vivax*VenipunctureFirst Response Malaria Antigen pLDH/HRP2 Combo (Premier Medical, India)pf-HRP2/pan-pLDHRound 2014*P. falciparum*/*P. vivax*12*P. falciparum*/*P. vivax*CareStart Malaria HRP-2/pLDH (Pf/pan) Combo (Access Bio, Inc., USA)pf-HRP2/pan-pLDHRound 1012*P. falciparum*/*P. vivax*CareStart Malaria HRP2/pLDH(Pf/Pv) Combo (Access Bio, Inc., USA)pf-HRP2/Pv-pLDHRound 207*P. falciparum*/*P. vivax*8. Ref.^[@CR30]^Endeshaw et al., 201084*P. falciparum*/*P. vivax*Finger prickParascreenPan/Pf (Zephyr Biomedicalsystems, India)pf-HRP2/pan-pLDHNot assessedNot assessed75*P. falciparum*/*P. vivax*9. Ref.^[@CR31]^Feleke et al., 20175*P. falciparum*/*P. vivax*VenipunctureCareStart Malaria HRP2/pLDH (Pf/PAN) Combo (Access Bio, Inc., USA)pf-HRP2/pan-pLDHRound 50.45*P. falciparum*/*P. vivax*10. Ref.^[@CR45]^Getnet et al., 2015CareStart Malaria HRP2/pLDH (Pf/PAN) Combo (Access Bio, Inc., USA)pf-HRP2/pan-pLDHRound 50.414*P. falciparum*/*P. vivax*6*P. falciparum*/*P. vivax* (5), *P. vivax*/*P. malariae* (1),11. Ref.^[@CR32]^Haanshuus et al., 2016ParaHIT-Total Ver. 1.0 Device 55IC204-10 (Span Diagnostics Ltd, India)pf-HRP2/pan-aldolaseRound 4027*P. falciparum*/Pan30*P. falciparum*/*P. vivax* (27), *P. falciparum*/*P. malariae* (2), *P. vivax*/*P. malariae* (1),12. Ref.^[@CR33]^Imwong et al., 20150VenipunctureSD BIOLINE Malaria Ag P.f/Pan POCT (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/pan-pLDHRound 508*P. falciparum*/*P. vivax*56*P. falciparum*/*P. vivax* (56)13. Ref.^[@CR34]^Iqbal et al., 200112*P. falciparum*/*P. vivax*Not specifiedOptiMAL (Pf-pLDH/pan-pLDH) (Biorad, France)Pf-LDH/pan-pLDHNot assessedNot assessed8*P. falciparum*/*P. vivax*14. Ref.^[@CR46]^Iqbal et al., 200224*P. falciparum*/*P. vivax*Finger prickICT Malaria Pf/Pv (ICT Diagnostics, Australia)pf-HRP2/Pv-pLDHNot assessedNot assessed12*P. falciparum*/*P. vivax*OptiMAL (Biorad, France)Pf/Pv -pLDHNot assessedNot assessed18*P. falciparum*/*P. vivax*15. Ref.^[@CR35]^Jahan et al., 201939*P. falciparum*/*P. vivax*Finger prickFirst response Malaria Ag, pLDH/HRP2 Combo Card test kit (Premier Medical Corporation Ltd.)pf-HRP2/pan-pLDHRound 5039*P. falciparum*/*P. vivax*016. Ref.^[@CR47]^Khorashad et al., 20145*P. falciparum*/*P. vivax*Finger prickMalaria 102 (p.f/p.v) POCT kits (InTec Products Inc., China)pf-HRP2/pan-pLDHNot found in WHO product testing recordsNot found in WHO product testing records5*P. falciparum*/*P. vivax*17. Ref.^[@CR36]^Kim et al., 20080VenipunctureOptiMAL (Biorad, France)Pf-LDH/pan-pLDHNot assessedNot assessed3*P. falciparum*/*P. vivax*3*P. falciparum*/*P. vivax*SD Malaria Antigen Pf/Pv (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/Pv-pLDHNot assessedNot assessed3*P. falciparum*/*P. vivax*18. Ref.^[@CR37]^Li et al., 2016Malaria Pv/Pf Test Device, Tycolpharm Co., Limited, UK)pf-HRP2/Pv-pLDHNot found in WHO product testing recordsNot found in WHO product testing records1*P. falciparum*/*P. vivax*3*P. falciparum*/*P. vivax*19. Ref.^[@CR49]^Meena et al., 20092*P. falciparum*/*P. vivax*Finger prickFalciVax (Orchid Biomedical Laboratories, India)pf-HRP2/Pv-pLDHNot assessedNot assessed1*P. falciparum*/*P. vivax*20. Ref.^[@CR44]^Mehlotra et al., 20190Finger prickSD BIOLINE Malaria Ag P.f/Pan (Standard Diagnostics Inc., Republic of Korea)pf-HRP2/pan-pLDHRound 50372*P. falciparum*/Pan24*P. falciparum*/*P. vivax* (13), *P. falciparum*/*P. malariae* (5), *P. falciparum*/*P. ovale* (1), *P. malariae*/*P. ovale* (2), *P. falciparum*/*P. malariae*/*P. ovale* (3),21. Ref.^[@CR38]^Moges et al., 20126*P. falciparum*/*P. vivax*Finger prickCareStart Malaria HRP2/pLDH (Pf/pan) (Access Bio, Inc., USA)pf-HRP2/pan-pLDHRound 13.026*P. falciparum*/Pan22. Ref.^[@CR39]^Ranjan P. and Ghoshal U, 20160VenipunctureNot reportedNot reported----3*P. falciparum*/*P. vivax*3*P. falciparum*/*P. vivax*23. Ref.^[@CR40]^Ratnawati et al., 200822*P. falciparum*/*P. vivax*Not specifiedRapid One-Step Malaria test (Arista Biologicals Inc., USA)pf-HRP2/pan-pLDHNot assessedNot assessed22*P. falciparum*/*P. vivax*24. Ref.^[@CR41]^Richter et al., 20044*P. falciparum*/*P. ovale* (3)*, P. falciparum*/*P. malariae* (1)Not specifiedThe Now Malaria test (Binax, Inc., USA)pf-HRP2/pan-aldolaseNot assessedNot assessed4*P. falciparum*/*P. ovale* (3)*, P. falciparum*/*P. malariae* (1)25. Ref.^[@CR50]^Sharew et al., 200910*P. falciparum*/*P. vivax*Not specifiedCareStart Malaria Pf/Pv Combo test (Access Bio, Inc., USA)pf-HRP2/Pv-pLDHRound 20.510*P. falciparum*/*P. vivax*26. Ref.^[@CR51]^van den Broek et al., 20067*P. falciparum*/*P. vivax*Finger prickOptimal-IT (Diamed AG, Switzerland)Pf-LDH/pan-pLDHNot assessedNot assessed7*P. falciparum*/PanNOW Malaria ICT (Binax, USA)pf-HRP2/pan-aldolaseNot assessedNot assessed8*P. falciparum*/Pan27. Ref.^[@CR42]^Woyessa et al., 20135*P. falciparum*/*P. vivax*Not specifiedCareStart Malaria Pf/Pv combo test (Access Bio, Inc., USA)pf-HRP2/Pv-pLDHRound 4014*P. falciparum*/*P. vivax*28. Ref.^[@CR43]^Yan et al., 201311*P. falciparum*/*P. vivax*Finger prickWondfo One Step Malaria HRP2/pLDH (P.f/Pan) Testpf-HRP2/pan-pLDHRound 1033*P. falciparum*/Pan21*P. falciparum*/*P. vivax*Malaria Pv/Pf test device (Tycolpharm Co., Limited, UK)pf-HRP2/Pv-pLDHNot found in WHO product testing recordsNot found in WHO product testing records8*P. falciparum*/*P. vivax*

Methodological quality of the included studies {#Sec13}
----------------------------------------------

The methodology and reporting of the selected studies varied highly (Fig. [2](#Fig2){ref-type="fig"}; Supplementary Fig. [1](#MOESM1){ref-type="media"}). All 28 included studies had cross-sectional designs. Most of the included studies (25/28, 89.3%) used a consecutive or random sample of patients. Two studies did not enrol a consecutive or random sample of patients^[@CR21],[@CR36]^. In another study^[@CR19]^, the sampling method for participants enrolled was unclear. Microscopic examination was used as the reference standard in 24 studies. PCR was used as a reference standard in 12 studies. The sensitivity and specificity of RDTs to detect *Plasmodium* mixed infections could not be calculated due to the inadequate data of the included studies to retrieve full 2 × 2 tables.Figure 2Methodological quality of the included studies.

Discordance between RDTs and microscopy {#Sec14}
---------------------------------------

All 24 studies reporting on the performance of RDTs for detecting mixed infections compared to microscopy were explicitly designed for this purpose^[@CR19],[@CR21],[@CR26]--[@CR28],[@CR30],[@CR31],[@CR33]--[@CR36],[@CR38]--[@CR44],[@CR46]--[@CR51]^ (Fig. [3](#Fig3){ref-type="fig"}). In total, six different RDT types including RDT types 2, 3, 4, 5 and 6 were included in the analysis. One study did not report the type of RDT used in their study^[@CR39]^. Six studies used more than one RDT type/brand in their studies^[@CR21],[@CR26],[@CR27],[@CR35],[@CR36],[@CR43]^. Four studies^[@CR28],[@CR33],[@CR36],[@CR44]^ reported mixed infections by RDT, but no mixed infections were reported by microscopy. The results of an individual study demonstrated that 18 studies in total^[@CR19],[@CR21],[@CR26],[@CR30],[@CR31],[@CR34]--[@CR36],[@CR40]--[@CR43],[@CR46]--[@CR51]^ had identical results for RDT and microscopy. Six studies^[@CR19],[@CR30],[@CR31],[@CR35],[@CR40],[@CR47]^ gave identical results for RDT type 3 and microscopy. Two studies^[@CR41],[@CR51]^ gave identical results for RDT type 2 and microscopy. Three studies^[@CR34],[@CR36],[@CR51]^ gave identical results for RDT type 4 and microscopy. Nine studies^[@CR21],[@CR26],[@CR36],[@CR42],[@CR43],[@CR46],[@CR48]--[@CR50]^ gave identical results for RDT type 6 and microscopy. The summary estimate of ORs between type 2 RDTs and microscopy to detect mixed infections ranged from 1.18 to 51.1. Based on the analysis of three included studies, the summary estimate of ORs between type 2 RDTs and microscopy was 4.33 (95% CI 0.24--79.8, p = 0.32, I^2^ = 96%). The summary estimate of ORs between type 3 RDTs and microscopy to detect mixed infections based on the analysis of 13 included studies was 8.46 (95% CI 2.75--26.1, p = 0.0002, I^2^ = 96%). When the four studies^[@CR28],[@CR33],[@CR39],[@CR44]^ that reported mixed infections detected by RDT but did not reported mixed infections by microscopy were ignored in the meta-analysis of type 3 RDTs and microscopy, the summary estimate of ORs between type 3 RDTs and microscopy to detect mixed infections based on the analysis of 13 included studies was 4.02 (95% CI 1.46--11.12, p = 0.007, I^2^ = 95%) (Supplementary file [1](#MOESM1){ref-type="media"}). The summary estimate of ORs between type 4 RDTs and microscopy to detect mixed infections based on the analysis of three included studies, was 0.99 (95% CI 0.48--2.04, p = 0.97, I^2^ = 8%). The summary estimate of ORs between type 5 RDTs and microscopy to detect mixed infections based on the analysis of one included study was 0.87 (95% CI 0.46--1.65). The summary estimate of ORs between type 6 RDTs and microscopy to detect mixed infections based on the analysis of nine included studies was 1.07 (95% CI 0.74--1.55, p = 0.71, I^2^ = 0%). Overall, the significant summary estimate of ORs between all types of RDTs and microscopy to detect mixed infections was found (OR = 3.33, 95% CI 1.66--6.68, p = 0.009, I^2^ = 94%).Figure 3Discordance between RDTs and microscopy.

The subgroup analysis of blood collection methods for microscopy was performed using 18 included studies. The results demonstrated that no subgroup difference (p = 0.55) was found among studies using blood from the finger prick method and those using blood from venipuncture. The summary estimate of ORs between all types of RDTs compared to those performing microscopy using blood from the finger prick method to detect mixed infections was significantly different among 11 studies (OR = 4.41, 95% CI 1.72--11.29, p = 0.002). The summary estimate of ORs between RDTs and microscopy using blood from the venipuncture method was significantly different among seven studies (OR = 3.04, 95% CI 1.44--6.43, p = 0.004) (Fig. [4](#Fig4){ref-type="fig"}).Figure 4The subgroup analysis of blood collection methods for microscopy.

Discordance between RDTs and PCR {#Sec15}
--------------------------------

Overall, 12 studies reported on mixed infections detected by both RDTs and PCR^[@CR21],[@CR26]--[@CR29],[@CR32],[@CR33],[@CR37],[@CR39],[@CR43]--[@CR45]^, as shown in Fig. [5](#Fig5){ref-type="fig"}. Among 12 studies, three different types of RDTs were reported including RDT types 2, 3, and 6. The summary estimate of ORs between type 2 RDTs and PCR to detect mixed infections was 8.21 (95% CI 4.51--15.0). The summary estimate of ORs between type 3 RDTs and PCR based on the analysis of six included studies to detect mixed infections was 4.05 (95% CI 0.73--7.84, p = 0.07, I^2^ = 97%). The summary estimate of ORs between type 6 RDTs and PCR based on the analysis of five included studies to detect mixed infections was 0.42 (95% CI 0.26--0.68, p = 0.0005, I^2^ = 0%). Another study with no description on the type of RDT showed that the summary estimate of ORs between RDTs and PCR to detect mixed infections was 0.84 (95% CI 0.17--4.3). Overall, the summary estimate of ORs between all types of RDTs and PCR to detect mixed infections was 1.17 (95% CI 1.54--0.53, p = 0.42, I^2^ = 96%). The subgroup analysis of detection of *Plasmodium* mixed-species infections between RDT and PCR found that the summary estimate of ORs between RDT and PCR was comparable in *P. falciparum* mixed infections with *P. vivax* (OR= 0.81, 95% CI 0.51--1.27, p = 0.36, I^2^ = 51%) and in *P. falciparum*/*P. vivax* and *P. falciparum* mixed infections with other *Plasmodium* spp. (OR: 6.96, 95% CI 1.50--32.4, p = 0.01, I^2^: 99%) (Fig. [6](#Fig6){ref-type="fig"}).Figure 5Discordance between RDTs and PCR. Figure 6The subgroup analysis of detection of Plasmodium mixed-species infections between RDT and PCR.

Publication bias {#Sec16}
----------------

Visual inspection of the funnel plots demonstrated no publications bias found because there was a symmetrical distribution of the included studies (geometric shapes) in the graph between the OR and SE (logOR) (Fig. [7](#Fig7){ref-type="fig"}). The publication bias was further assessed with Egger\'s test. Egger\'s test showed no publication bias due to the small-study effects found (p-value = 0.166) (Table S2). Therefore, the summary estimates of ORs in the present meta-analysis were not confounded by publication bias of the included studies.Figure 7The funnel plot.

Discussion {#Sec17}
==========

This is the first study to summarize the available data on the discrepancy between RDTs and two gold/reference standards for the detection of malaria mixed infections. The summary ORs of discrepancies of RDT types 2, 3, 4, 5, and 6 in detecting malaria mixed infections compared to microscopy were 4.33, 8.46, 0.99, 0.87, and 1.07, respectively. Even though the overall summary estimate of ORs was significantly observed, subgroup analysis of RDT types demonstrated that only RDT type 3 could detect a significantly higher proportion of *Plasmodium* mixed infections than the microscopic method. Among the 8 studies conducted in Ethiopia^[@CR27],[@CR30],[@CR31],[@CR38],[@CR42],[@CR45],[@CR48],[@CR50]^, only a study by Ashton et al.^[@CR27]^ revealed a considerable difference in the proportion of mixed infections detected by RDT types 2 and 3 compared with microscopy. From 297 blood samples of *P. falciparum* mono-infection confirmed by the microscopy, 213 (213/297: 71.7%), 224 (224/297: 75.4%), and 223 (223/297: 75.1%) samples were interpreted as mixed infections by CareStart (AccessBio, USA), ICT Combo (ICT Diagnostics, South Africa), and ParaScreen (Zephyr Biomedicals, India), respectively. The remaining studies conducted in Ethiopia had identical numbers of mixed infections in 2 studies^[@CR31],[@CR50]^ and high numbers of mixed infections in three studies^[@CR38],[@CR42],[@CR48]^,another study conducted in Ethiopia demonstrated more mixed infections detected by microscopy (84 cases) than by RDT (75 cases)^[@CR30]^. Another important difference in the proportion of mixed infections detected by RDT type 3 compared with microscopy was also demonstrated in the study conducted in Madagascar by Mehlotra et al., 2019 during 2015--2016 because 84.6% of blood samples with confirmed *P. falciparum* mono-infections by microscopy and by LDR-FMA analysis were positive for both the Pf-HRP2 and pan-pLDH test bands^[@CR44]^. In addition, an important difference in the proportion of mixed infections detected by RDT type 3 compared with microscopy was also demonstrated in the study conducted in Madagascar by Berzosa et al. because 0.87% of blood samples with confirmed *P. falciparum* mixed infections by PCR were false positive for *Plasmodium* mixed infections by RDT type 3 (212 cases, 12.3%)^[@CR28]^.

The high proportion of mixed infections detected by RDT types 2 and 3 compared with microscopy reported in the included studies by Ashton et al., Mehlotra et al., and by Berzosa et al. may be due to the consistent false positive Pan-pLDH test lines among *P. falciparum* samples at high parasite densities, as reported in RDTs targeting Pv-pLDH^[@CR53]^. A high parasite density of *P. falciparum* can induce positivity of the pLDH band on RDTs, giving false positives of non-falciparum species^[@CR28]^. The false positive on Pan-pLDH test lines among *P. falciparum* samples at high parasite densities may be possible to use as the detection limit of the SD Bioline Malaria Ag P.f/Pan RDT used in the study by Mehlotra et al. because the mean parasitaemia level in samples that were positive for both the PfHRP2 and pan-pLDH test bands was significantly higher than that in those that were positive only for the PfHRP2 band^[@CR44]^. In addition, the included study by Ashton et al., 2010, demonstrated the false-positive results in Pan-pLDH test lines of *P. falciparum* (38%) and *P. vivax* samples which might cause by high parasite densities (\> 5,000 parasites/µl)^[@CR27]^. Therefore, high *P. falciparum* or *P. vivax* parasitaemia could lead to incorrect interpretation of RDTs, particularly interpretation of mixed infections. The discordance between RDT types 2 or 3 and microscopy can be explained because RDT type 3 is specific to Pf-HRP2 and pan-pLDH and RDT type 2 is specific to pan-aldolase and thus cannot distinguish between a *P. falciparum* infection and a mixed infection when both test lines are observed. Other possible causes of discrepancy were false positive results from patients who had received any anti-malarial treatment in the previous four weeks as reported by the authors, parasitized erythrocytes cytoadhered to the microvasculature that were not seen in the peripheral circulation or on blood films although antigen continued to be released yielding RDT positivity^[@CR54]^, or a low parasite density of the mixed infection that was too low to be seen by the microscopists but with sufficient parasite antigen to yield RDT positivity^[@CR55]^.

The meta-analysis of RDTs and microscopy had no significant discrepancy among RDTs type 2, 4, and 6. In this analysis, the summary results of RDT type 5 performed by Iqbal et al.^[@CR46]^ and RDTs performed by Ranjan and Ghoshal^[@CR39]^ could not be interpreted because there were a small number of studies for subgroup analysis. Overall, the evidence was strong for RDT types 3 and 6 mainly because a large number of studies were available for inclusion. However, the summary estimate of RDT type 3 demonstrated high heterogeneity among the included studies (I^2^ = 96%) when compared to those of RDT type 6 (I^2^ = 0%). In this study, more than half of the studies (n = 18) relied solely on microscopy as the gold/reference standard for *Plasmodium* species identification. Therefore, the discordant results between RDTs and microscopy demonstrated in the present study might be due to the imperfect nature of the gold/reference standard because mixed infections with *P. falciparum* could be missed by microscopy. Because of these results, RDT types 2 and 3 could rectify the diagnosis of *P. falciparum* in mixed-species infections that might be missed by the microscopy method. These results supported that the selection of the most appropriate RDTs relative to malaria epidemiology and are very crucial to differentiated mixed infections because the identification of *Plasmodium* mixed-species infections would facilitate appropriate treatment with artemisinin-based combination therapies (ACTs), which could eliminate any mixed infection even if mixed infections were not detected by the gold/reference standard, the microscopy method^[@CR56]^.

Recently, the sensitivity and specificity for the detection and identification of malarial parasites have been improved using the Nested-PCR method, which amplifies the *18s rRNA* gene^[@CR57]^. It has been proven to be more sensitive and accurate than routine diagnostic microscopy and provides the advantage of a higher proportion of detection in cases of mixed-species infections^[@CR57]^. In the present study, 12 included studies used PCR as a reference standard for *Plasmodium* species identifications. The discrepancy between RDT type 3 and PCR (OR = 4.05) appeared to be heavily influenced by the included studies by Berzosa et al. and by Mehlotra et al. in which the individual ORs were extremely high (19.9 and 93.2, respectively). This affirms that when compared with using PCR as the gold/reference standard, the high discrepancy between RDT type 3 targeting Pf-HRP2 and pan-pLDH leads to incorrect interpretation of mixed infections by RDTs, as we discussed earlier in the discrepancy of RDT type 3 and microscopy. The false positive results of RDTs when detecting mixed infections may be associated with decreased age because of the high prevalence of malaria in children, particularly children under 5 years of age, who are likely to develop severe malaria with high parasitaemia^[@CR58],[@CR59]^. The present meta-analysis demonstrated that the significant discordance between RDTs and PCR was found in studies using RDT type 6, which detects the pf-HRP2/Pv-pLDH antigen of malaria parasites. RDT type 6 could detect a lower proportion of *Plasmodium* mixed infections than the PCR reference method. This finding was similar to three previous studies^[@CR21],[@CR60],[@CR61]^. Therefore, the lower proportion of *Plasmodium* mixed infections detected by RDT type 6 than by PCR demonstrated in the present study might be due to the lower sensitivity and specificity of RDTs than of PCR methods. In practice, PCR methods have a higher sensitivity (approximately 0.0001 parasites/µL) than RDT (approximately 100 parasites/µL) and microscopy (approximately 50--500 parasites/µL)^[@CR8]^, which allows for the detection of *Plasmodium* mixed infections at a low parasite density, which are routinely missed in microscopy^[@CR62]^. The subgroup analysis of *Plasmodium* mixed-species infections as reported by the 6 included studies demonstrated that a comparable proportion detected *P. falciparum* mixed infections with *P. vivax* between RDTs and PCR, while there was a significant difference in the proportion that detected *P. falciparum*/*P. vivax* and *P. falciparum* mixed infections with other *Plasmodium* species. This subgroup analysis suggested that RDTs had identical results with PCR in detecting *P. falciparum* and *P. vivax* mixed infections. In contrast, RDTs had discordant results with PCR in detecting *P. falciparum* mixed infections with other *Plasmodium* species. Nevertheless, these results should be further confirmed by full experimental studies.

The present study had limitations. First, RDTs targeting HRP-2 and pan-pLDH or RDTs targeting HRP-2 and pan-aldolase are likely to be positive in *P. falciparum* mono-infections or mixed-species infections. Regarding this limitation of the RDTs in the included studies, the summary estimates of ORs between RDT types 2 and 3 and microscopy need to be carefully interpreted. Second, the overall evidence of the analysis between RDTs and PCR was weak, mainly because few studies were available for inclusion. Second, the lower sensitivity and specificity of RDTs than those of PCR was due to the limits of detection. The WHO has suggested that the clinical sensitivity of RDTs is highly dependent on conditions including the level of parasite density and the subset of any population, such as young children or pregnant women; thus, the interpretation of RDTs must be carefully interpreted^[@CR63]^. Third, the sensitivity and specificity of RDTs compared to the gold standard could not be calculated due to data on individual patient were lacking and the data on whether patients who gave positive results for RDT were the same patients who gave positive results for the gold/reference standard or not, as most of the included studies report the number of positive separately between RDTs and microscopy/PCR. Fourth, some eligible studies might have been missed through the search strategy. However, the additional search of reference lists of the included studies and searches of other sources such as Google search and Google Scholar, and performing extensive searching of reference lists and searching other sources with broad search terms, helped to reduce this limitation by further increasing the number of included studies. Fifth, the study aimed to clarify what proportion of *Plasmodium* mixed-infections could not be confirmed by a positive RDT result, and the proportion of *Plasmodium* mixed infections were often not the primary target of studies, which led to a low number of studies that were focused on mixed infections. In light of these, although the current data are still suggestive of high discrepancies of RDT type 3 for detecting *Plasmodium* mixed infections in comparison to microscopy and of RDT type 6 for detecting *Plasmodium* mixed infections in comparison to PCR methods, they provided a critical advantage on malaria treatment in resource-limited settings in which the results of microscopy could not be obtained. Further studies focused on the diagnosis of *Plasmodium* mixed-species infections by RDTs are needed to provide a better understanding of the performance of RDTs, guide the development of an improved diagnostic test for *Plasmodium* mixed infections, and facilitate the appropriate treatment of patients with ACTs. This will help with the elimination of malaria in endemic and non-endemic areas where laboratory capacity is limited.

Conclusion {#Sec18}
==========

In conclusion, the present study suggested that malaria RDTs showed some discordant results with microscopy and PCR. The selection interpretation of RDTs can facilitate a better diagnosis of *Plasmodium* mixed-species infections and appropriate treatment of malaria patients in endemic and non-endemic settings.
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RDTs

:   Rapid diagnostic tests

PCR

:   Polymerase chain reaction

CI
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HRP2

:   Histidine-rich protein 2

LDH
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:   Quality assessment of diagnostic accuracy studies
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